A 3D View: Janus Kinase Inhibition as a Novel Approach to Rheumatoid Arthritis: Emerging Data Impacting Our Treatment Paradigms
Maria Greenwald, MD
Desert Medical Advances
Palm Desert, CA
Gregg J. Silverman, MD
Professor of Medicine and Pathology
Director, Laboratory of B cell Immunobiology
NYU School of Medicine
New York, NY
This live activity is focused on use of biologics and targeted therapies in the management of rheumatoid arthritis.
This CME initiative is designed to meet the educational needs of rheumatologists, rheumatology nurses and other healthcare providers involved in the treatment of patients with rheumatoid arthritis.
After completing the CME activity, learners should be better able to:
- Review current understanding of rheumatoid arthritis pathophysiology with focus on the cytokine signaling pathways underlying chronic inflammation
- Describe how specific cytokines involved in RA pathophysiology signal through the Janus kinase (JAK) pathway and the mechanism of action, selectivity and effects of new and emerging JAK inhibitors
- Discuss new data from clinical trials of approved and investigational JAK inhibitors and their efficacy/safety profile across the spectrum of rheumatoid arthritis
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the treatment and management of patients with rheumatoid arthritis.
1.5 ANCC Contact Hour(s)
CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.5 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Gregg J. Silverman serves as a consultant for Amgen, BMS, Roche, and Sanofi. His spouse is employed by Gilead.
Dr. Maria Greenwald is a Speakers Bureau member for Lilly and has received non-CE fees. She has conducted research for Lilly, Galapagos, Gilead, Astellas, Pfizer, and Abbvie.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lisa Crenshaw, Program Manager for Med Learning Group has nothing to disclose.
Flavia Piazza, PhD, VP, Medical and Scientific Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lectures, Drs. Silverman and Greenwald may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to the Med Learning Group.
You will receive your certificate via email within 30 days.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: November 30, 2017
EXPIRATION DATE: November 30, 2018
This educational activity provides training necessary for licensed attendees to maintain state licensing requirements. The tuition for this educational activity is subsidized in part by unrestricted educational grants, including for those attendees who have successfully completed the state licensing requirements for their respective fields. This subsidy is reflected in the registration fees for this activity.
Copyright © 2017 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.